On March 13, 2025 ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) reported a strategic partnership with a leading biotechnology company with a multi-billion-dollar market capitalization to advance the discovery and development of Antibody-Drug Conjugates (ADCs) and bispecific antibodies for the treatment of cancer (Press release, ImmunoPrecise Antibodies, MAR 13, 2025, View Source [SID1234651145]). This collaboration focuses on leveraging contract research expertise while integrating IPA’s proprietary B-cell Select platform and artificial intelligence-driven discovery capabilities to enhance the efficiency and precision of therapeutic development.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, the partnership will encompass the discovery, lead characterization, optimization, and preclinical-grade production of multiple antibody-based therapeutics, with a focus on developing highly selective and effective cancer treatments. IPA’s proprietary multi-omics AI-driven modeling and discovery platform, combined with its B-cell Select technology, will be integrated at key stages to optimize therapeutic selection and accelerate lead development.
The agreement, valued at an initial $8 million with the potential to expand to $10 million based on program progression, will span 18 to 24 months, integrating artificial intelligence across the workflow to enhance discovery and optimization. This collaboration aims to streamline the path from target discovery to preclinical candidate selection, marking a significant step toward advancing next-generation biologics for cancer treatment.
"This partnership underscores the power of combining AI-driven discovery with advanced antibody engineering," said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. "With the purchase order secured and work already underway, we are actively leveraging our proprietary B-cell Select platform and LENSai technology to accelerate the development of highly targeted cancer therapeutics. This collaboration highlights IPA’s role in shaping the future of next-generation biologics with data-driven precision and efficiency."